Skip to the content
logo mainlogo darklogo light
logo main
logo main
  • Home
  • Team
  • Pipeline
  • Science
  • News
  • CONTACT
July 12, 2023

Prof. Burkhard Sträter

Burkhard is specialized in regulatory affairs and pharmaceutical law. He founded his lawfirm in 1987, advising pharmaceutical companies and medical device manufacturers on clinical

Read More
by piomat
July 12, 2023

Willem Bulthuis

Willem Bulthuis is dedicated since 2015 to supporting global venturing ecosystems, as co-founder, board member and advisor at ventures, as business angel, as venture partner at VC

Read More
by piomat
July 12, 2023

Dr. Karsten Ottenberg

Karsten is the former CEO and Executive of multinational corporates including the BSH Home Appliances Group, Giesecke & Devrient and Philips Semiconductors (now NXP). Karsten b

Read More
by piomat

2024 | Copyright ©AATec Medical GmbH

  • Imprint
  • Privacy Policy

  • HomeHome
  • TeamTeam
  • PipelinePipeline
  • ScienceScience
  • NewsNews
  • CONTACTCONTACT

Follow us on

A Versatile Platform for Global Respiratory Health

Beyond NCFB, our recombinant AAT platform offers significant potential in major respiratory markets like COPD and asthma, where it targets underserved neutrophilic inflammation. It also offers significant potential in airway infections, leveraging ATL-105’s antiviral and bacteriostatic effects to reduce exacerbations. In the long-term our AAT products could help close critical care gaps in pulmonary indications including acute respiratory distress syndrome (ARDS) and bronchiolitis obliterans syndrome (BOS).

Non-CF Bronchiectasis (NCFB)

Our lead indication non-cystic fibrosis bronchiectasis (NCFB) is a debilitating chronic respiratory disease marked by permanent airway enlargement and a “vicious vortex” of persistent neutrophilic inflammation and recurrent infections.

Despite its severity, there are currently treatment options are still limited for the over 3 million patients in Western countries alone. This represents a massive unment medical need and a significant market opportunity, with a peak sales potential of $1.8 billion for ATL-105 in this indication alone.

ATL-105 provides a compelling biological rationale for the treatment of NCFB, as its multimodal action directly targets the underlying drivers of tissue destruction by irreversibly inhibiting neutrophil proteases, restoring the airway’s cytokine balance.